Below are the most recent publications written about "Quinolones" by people in Profiles.
-
Richard NP, Pippa R, Cleary MM, Puri A, Tibbitts D, Mahmood S, Christensen DJ, Jeng S, McWeeney S, Look AT, Chang BH, Tyner JW, Vitek MP, Odero MD, Sears R, Agarwal A. Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemia. Oncotarget. 2016 Dec 20; 7(51):84214-84227.
-
Molina-Torres CA, Barba-Marines A, Valles-Guerra O, Ocampo-Candiani J, Cavazos-Rocha N, Pucci MJ, Castro-Garza J, Vera-Cabrera L. Intracellular activity of tedizolid phosphate and ACH-702 versus Mycobacterium tuberculosis infected macrophages. Ann Clin Microbiol Antimicrob. 2014 Apr 04; 13:13.
-
Gopalakrishna G, Aggarwal A, Lauriello J. Long-acting injectable aripiprazole: how might it fit in our tool box? Clin Schizophr Relat Psychoses. 2013; 7(2):87-92.
-
Podos SD, Thanassi JA, Leggio M, Pucci MJ. Bactericidal activity of ACH-702 against nondividing and biofilm Staphylococci. Antimicrob Agents Chemother. 2012 Jul; 56(7):3812-8.
-
Roboz GJ, Wissa U, Ritchie EK, Gergis U, Mayer S, Scandura JM, Christos PJ, Feldman EJ. Are low-intensity induction strategies better for older patients with acute myeloid leukemia? Leuk Res. 2012 Apr; 36(4):407-12.
-
Kim HY, Wiles JA, Wang Q, Pais GC, Lucien E, Hashimoto A, Nelson DM, Thanassi JA, Podos SD, Deshpande M, Pucci MJ, Bradbury BJ. Exploration of the activity of 7-pyrrolidino-8-methoxyisothiazoloquinolones against methicillin-resistant Staphylococcus aureus (MRSA). J Med Chem. 2011 May 12; 54(9):3268-82.
-
Pucci MJ, Podos SD, Thanassi JA, Leggio MJ, Bradbury BJ, Deshpande M. In vitro and in vivo profiles of ACH-702, an isothiazoloquinolone, against bacterial pathogens. Antimicrob Agents Chemother. 2011 Jun; 55(6):2860-71.
-
Wiles JA, Bradbury BJ, Pucci MJ. New quinolone antibiotics: a survey of the literature from 2005 to 2010. Expert Opin Ther Pat. 2010 Oct; 20(10):1295-319.
-
Pucci MJ, Ackerman M, Thanassi JA, Shoen CM, Cynamon MH. In vitro antituberculosis activities of ACH-702, a novel isothiazoloquinolone, against quinolone-susceptible and quinolone-resistant isolates. Antimicrob Agents Chemother. 2010 Aug; 54(8):3478-80.
-
Vera-Cabrera L, Campos-Rivera MP, Escalante-Fuentes WG, Pucci MJ, Ocampo-Candiani J, Welsh O. In vitro activity of ACH-702, a new isothiazoloquinolone, against Nocardia brasiliensis compared with econazole and the carbapenems imipenem and meropenem alone or in combination with clavulanic acid. Antimicrob Agents Chemother. 2010 May; 54(5):2191-3.